Dr. Lal PathLabs recorded 41.48% jump in consolidated profit after tax to Rs 80.50 crore on 15.15% increase in revenues to Rs 365.60 crore in Q2 September 2019 over Q2 September 2018.Profit before tax (PBT) stood at Rs 102.3 crore in Q2 September 2019 compared with Rs 88.1 crore in Q2 last year, a growth of 16.1%.
Operating revenue increased by 15.1% in Q2 September 2019 to Rs 365.6 crore as against Rs 317.5 crore in the previous year same quarter. Underlying patient volume growth is 12.1% during the quarter.
Normalised EBITDA (after adjustment for stock based compensation, CSR cost & impact of Ind AS 116) for Q2 September 2019 grew 15.7% to Rs 104.7 crore from Rs 90.5 crore in the same quarter last year. Normalised EBITDA Margin ex Ind AS 116 at 28.6% for Q2 September 2019.
The company declared an interim dividend of Rs 6 per share.
Shares of Dr. Lal PathLabs declined 2.91% to Rs 1451.80 on Friday, 8 November 2019.
Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)